Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the needle vaccines are garbage , we need a pill AEZS delivers and we get rich
OK bottom line we got this under wraps FDA will release , kaboom
u smart,god bless all
spce was on my watch list never took a bite , dam
i'm ready with a large pile of powder AEZS
actually a lot of young traders make large but the ones that complain and wine obviously don't AEZS is a work in progress maybe a 10 bagger , will see
bashing a game changer makes no sense ,sad these young turds no nothing when it comes to making money AEZS is well funded and ready for a fore front position
true,hold tight,god bless all and good luck to us
I hope this comes true ASAP. This is torture to see price below $1 for so long whereas it is said to have many catalysts …
TEN WILL COME SOON THE SHORTS WILL GET KILLED..
bro ,macrilen will have many uses,what about cancer cachexia,end of phase 2,thats the key,other uses for macrilen and pedi test will be much bigger than adult test,again its for an unmet need,throw in covid pill vaccine and all other preclinicals and u got a lot of catalysts coming our way,im not saying she will hit 30 bucks but 10 bucks is very much within reason imo
11 employees company… I am afraid not going to have successful products produced at all…can only count on some pr pushing the share price up..
they are okay with you ... the hope is to come out on par with this living dead ....
write to the company and even if it is useless but at least let them know that we are pissed off with this incapable management
they don't even have an internal investor office ... pathetic
Jenene Thomas <jenene@jtcir.com>
Very bad indeed. Can only hope for pr on covid pill and then time to sell off this stock…
so, there is only 1 phase three study and the macrilen has only 1 use as a test the text is just words ... the problem is that there is no trust in management and investors see no value here and the share price shows it .... even if in 2023 they approved this test for adolescents, a test would always be and would not lead to large cash inflows.
they have not been able to market the test in Europe and England for 4 years ... but it's okay ... so the salary always comes and they can do shit with ice buckets ....
This is aezs the only hope here is that a decent pr on the covid pill will come out and come out at no loss ....
so, there is only 1 phase three study and the macrilen has only 1 use as a test the text is just words ... the problem is that there is no trust in management and investors see no value here and the share price shows it .... even if in 2023 they approved this test for adolescents, a test would always be and would not lead to large cash inflows.
they have not been able to market the test in Europe and England for 4 years ... but it's okay ... so the salary always comes and they can do shit with ice buckets ....
This is aezs the only hope here is that a decent pr on the covid pill will come out and come out at no loss ....
we need the pill and we boom https://thehighwire.com/videos/episode-221-the-mrna-insider/ AEZS
i agree,the 1st time i had the flu shot was 1 of the wort nts in my life but like i said everyone in the family said u have to get it for us
https://chemicalviolence.com/2021-06-22-vaccinated-people-600percent-more-die-covid-variants.html# livendi I knew all this watching and listening to the Highwire.com and others it weakens u , changes your dna, makes u more prone to failure , your body knows how to deal with viruses , the media has been tricking us , cdc made the wrong protocol in the beginning, inducing coma and then being put on a ventilator was 90% chance of death and then as well hospital's were fudging numbers bc they got huge money for corona virus deaths
my family made me get it,cant fight city hall
I aint taking no vaccine , they can f off, maybe take a pill https://chemicalviolence.com/#
https://www.naturalnews.com/2021-05-25-everyone-vaccinated-will-die-within-two-years.html#
well worth the wait if approved because eu and row will follow fda approval and thats just 1 use for macrilen,even if fda approves 1 of the other uses for macrilen,either cancer cachexia or tbi,what will sales of macrilen balloon 2,long term play here but it could jump short term 2 especially with covid pill vaccine trials and other precliclincals aezs working on,god bless all
Phase 3 result in 2023…share price before that will be very pathetic then.
looked it up ,phase 3 for tbi,clinical trial # nct04867317 but trial wont end till 2023,again macrilen will have many uses,god bless all
i see two phase 3 studies in usa for tbi and cancer cachexia,someone posted the info the other day on another sight,i dont know why klauss isnt talking about it,maybe because novo owns rights in n america but just like the data was used from fda to eu to approve as the adult test,aezs will do the same if approved by fda in usa,look it up again,god bless all and good luck 2
sorry but there is only one phase 3 study and it is always to use the macrilen as a test, nothing more ... the second phase three study where do you see it sorry?
the rest are just preclinical studies
so macrilens 2 phase 3 trials in usa for cancer cachexia and tbi are worthless huh,do u have any idea what macrilens sales will be if macrilen is approved for these 2 indications,it would be gigantic and pedi approval is for an unmet need,again not a small thing,no way to test kids for ghd,if u dont have patience this stock isnt for u,just hold,much much better days coming,god bless all
Very bad, I should have sold all at $3 in March !
here there is no more trust you do not see the volume, the continuous decline ... the market knows very well that macrilen is not a good deal and that it will not bring any value here ... if it is approved in 2024 what do you think it is do you bring to the company? 3.4 million dollars which added to the 3 of adults make 7 million a year ... it's funny ... it's not even worth considering .... and the rest? only preclinical studies that will never see a sequel. This is the reality ... Gentlemen have been studying macrilen for over 15 years, spending millions and millions of dollars ... if there was value after all this time, don't you think it would have already been considered?
this is reality the rest are just dreams
here there is no more trust you do not see the volume, the continuous decline ... the market knows very well that macrilen is not a good deal and that it will not bring any value here ... if it is approved in 2024 what do you think it is do you bring to the company? 3.4 million dollars which added to the 3 of adults make 7 million a year ... it's funny ... it's not even worth considering .... and the rest? only preclinical studies that will never see a sequel. This is the reality ... Gentlemen have been studying macrilen for over 15 years, spending millions and millions of dollars ... if there was value after all this time, don't you think it would have already been considered?
this is reality the rest are just dreams
do not fool yourself this test is another failure when you think it could bring another 3 million dollars .... uauuuuu
I'm sorry to say it but there is no value here .... macrilen is just an excuse to continue taking wages for 15 years but it was a failure .... the covid vaccine does not know what happened done but now it's late .... there is no trust and the price continues to drop in the most total indifference of an incompetent management. This is reality'. They will continue to take salaries until 2023 then another dilution etc. etc. etc....
I was really wrong. think they could do something good.
alot of factors contributed to that,covid,ins in usa being cheap,it will get better with new licensing deals and with time but the key is pedi approval for test which is for an unmet need,no way to test kids,also the other uses for macrilen is another big key,u know its in phase 3 in usa for tbi and cancer cachexia and preclinicals for lou gehrigs disease,a little more patience is what we need although it does suck seeing it go down,just a matter of time though as way too many different catalysts coming imo,god blessall and good luck to us
Macrilen product sale through Novo Nordisk is pathetic. This is the reason on poor management creditability.
i'm living at 1.8 million lake front cottage , ready to freak everyone out and buy a shitload , u will know when I make a move AEZS
dont have the xtra funds for that rt now,gonna buy a house cash in mass and u know mass houses are expensive,got 100k in aezs and tmdi,my broker handles pension fund but cant touch till 60,god bless and good luck to us
need diamond hands AEZS
Dogecoin will hit 9/7cent and bounce to 16/18.. AEZS is ready for a 150
again the only thing needed here is patience,god bless all
we will win this one , we need time , flu season is in the fall , November rain AEZS
u have alot of issues with AEZS give it a rest
The issue is that AEZS does not own the product at all…
A research team at the University of Würzburg is testing a novel approach for a vaccine against the coronavirus - for swallowing. The advantages: Comparatively cheap to produce, easy to administer and relatively stable even at normal temperatures.
If Prof. Thomas Rudel from the Julius Maximilians University of Würzburg and the biopharmaceutical company Aeterna Zentaris in Frankfurt have their way, there could possibly be significant reinforcements in the fight against the global corona pandemic in the future: a vaccination that does not come with the syringe rather than as a capsule that can easily be swallowed. Preclinical development has already started.
Thomas Rudel holds the chair for microbiology at the Julius Maximilians University of Würzburg (JMU) and had the idea for oral vaccination a good year ago Typhoid infection is at work ". The oral typhoid vaccine is based on a special strain of bacteria, Salmonella Typhi Ty21a.
Rudel and the scientists in his laboratory are now also working with this bacterial strain - with a significant modification: "We have programmed the bacteria to produce SARS-CoV-2 antigens," explains the microbiologist. Rudel was supported by the microbiologist Dr. Birgit Bergmann. Protected from gastric acid attack in a capsule, the bacteria are supposed to develop their effect in the human small intestine after passing through the stomach. The scientific approach assumes that the bacteria can present the antigens to the immune system there.
"Special cells in the intestinal wall are supposed to ensure that bacteria and the antigens are absorbed by immune cells and transported further into lymphoid tissue," says Rudel. There they could in turn activate other cells of the immune system - so-called B and T cells - and set an immune response in motion. Rudel hopes that, if successful, this immune response will be so strong that all human mucous membranes will be put on alert and, as a result, coronaviruses will be prevented from entering the body there.
The advantages are obvious
In order to remain effective against newly emerging virus mutations, Rudel's team developed the bacteria in such a way that they produce not one, but two antigens at the same time. So if one antigen is only weakly effective due to a virus change, the second antigen could serve as a “safety anchor”: It is based on a gene that has been shown to mutate only rarely.
The vaccine from the Franconian laboratory would also have several advantages: It would be cheap to manufacture, easy to administer and relatively stable even at normal temperatures.
Optimistic as well as realistic
The development of the vaccine strains and the preclinical work is financially supported by Aeterna Zentaris GmbH. The pharmaceutical company would undertake the subsequent clinical tests. Rudel is confident that the necessary permits could be obtained relatively quickly. A few years ago, Aeterna Zentaris had been working with a similar process on a vaccine against prostate cancer, which was about to start clinical trials and had been officially approved for clinical examination. The team can now build on these experiences.
Nevertheless, Rudel is cautiously optimistic. There is no guarantee thbat an oral vaccination against Covid-19 will soon be available in pharmacies, warns Rudel. After all, many active ingredients have failed even at a late stage of development because they were not sufficiently effective or had unexpected and undesirable effects.
Followers
|
301
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
18784
|
Created
|
05/09/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |